Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000185363
Created by
admin on Fri Dec 15 16:04:30 UTC 2023 , Edited by admin on Fri Dec 15 16:04:30 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB10880
Created by
admin on Fri Dec 15 16:04:30 UTC 2023 , Edited by admin on Fri Dec 15 16:04:30 UTC 2023
|
PRIMARY | |||
|
SUB130440
Created by
admin on Fri Dec 15 16:04:30 UTC 2023 , Edited by admin on Fri Dec 15 16:04:30 UTC 2023
|
PRIMARY | |||
|
4F35XG0149
Created by
admin on Fri Dec 15 16:04:30 UTC 2023 , Edited by admin on Fri Dec 15 16:04:30 UTC 2023
|
PRIMARY | |||
|
N0000175629
Created by
admin on Fri Dec 15 16:04:30 UTC 2023 , Edited by admin on Fri Dec 15 16:04:30 UTC 2023
|
PRIMARY | Increased Histamine Release [PE] | ||
|
N0000171131
Created by
admin on Fri Dec 15 16:04:30 UTC 2023 , Edited by admin on Fri Dec 15 16:04:30 UTC 2023
|
PRIMARY | Allergens [Chemical/Ingredient] | ||
|
SUB49530
Created by
admin on Fri Dec 15 16:04:30 UTC 2023 , Edited by admin on Fri Dec 15 16:04:30 UTC 2023
|
PRIMARY | |||
|
N0000184999
Created by
admin on Fri Dec 15 16:04:30 UTC 2023 , Edited by admin on Fri Dec 15 16:04:30 UTC 2023
|
PRIMARY | Fur [Chemical/Ingredient] | ||
|
4F35XG0149
Created by
admin on Fri Dec 15 16:04:30 UTC 2023 , Edited by admin on Fri Dec 15 16:04:30 UTC 2023
|
PRIMARY | |||
|
895515
Created by
admin on Fri Dec 15 16:04:30 UTC 2023 , Edited by admin on Fri Dec 15 16:04:30 UTC 2023
|
PRIMARY | RxNorm | ||
|
N0000184306
Created by
admin on Fri Dec 15 16:04:30 UTC 2023 , Edited by admin on Fri Dec 15 16:04:30 UTC 2023
|
PRIMARY | Cell-mediated Immunity [PE] | ||
|
N0000185001
Created by
admin on Fri Dec 15 16:04:30 UTC 2023 , Edited by admin on Fri Dec 15 16:04:30 UTC 2023
|
PRIMARY | Increased IgG Production [PE] |
ACTIVE MOIETY
